Quantedge Capital
HRMY icon

Quantedge Capital’s Harmony Biosciences HRMY Stock Holding History

Quantedge Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.72M Buy
94,800
+70,800
+295% +$2.74M 0.4% 15
2026
Q2 		$874K Sell
24,000
-26,500
-52% -$836K 0.66% 27
2026
Q1 		$1.41M Sell
50,500
-10,800
-18% -$354K 0.77% 27
2025
Q4 		$2.29M Sell
61,300
-3,400
-5% -$112K 1.09% 23
2025
Q3 		$1.78M Buy
+64,700
New +$2.23M 0.98% 19
2023
Q2 		– Sell
-10,700
Closed -$349K – 147
2023
Q1 		$349K Sell
10,700
-25,200
-70% -$1.15M 0.14% 102
2022
Q4 		$1.98M Buy
35,900
+2,900
+9% +$159K 0.66% 48
2022
Q3 		$1.46M Buy
33,000
+5,500
+20% +$268K 0.45% 70
2022
Q2 		$1.34M Buy
+27,500
New +$1.24M 0.27% 104

Other funds holding HRMY

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Quantedge Capital's HRMY Position: Q3 2026 in Review

Quantedge Capital increased its Harmony Biosciences (HRMY) stake by 295% in Q3 2026, buying an estimated $2.74M and bringing the position to 94,800 shares worth $3.72M. The position accounts for 0.4% of the portfolio, ranked #15.

Quantedge Capital first reported a position in HRMY in Q2 2022 and has held it in 9 quarters since. 279 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Quantedge Capital held 94,800 shares of Harmony Biosciences worth $3.72M as of Q3 2026.
  • Quantedge Capital bought 70,800 Harmony Biosciences shares in Q3 2026, an estimated $2.74M.
  • Harmony Biosciences made up 0.4% of Quantedge Capital's portfolio in Q3 2026, its #15 holding.
  • Quantedge Capital first reported a position in Harmony Biosciences in Q2 2022 and has held it in 9 quarters since.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Quantedge Capital's 13F filing for Q3 2026, filed 10 Nov 2026.